Since the majority of patients with ovarian cancer present with advanced stages of disease, more effective systemic approaches are needed to add to the benefits of surgical staging and debulking. New combinations of taxoids with cisplatin have prolonged survival, and other chemotherapeutic agents are being evaluated. Immunotherapy, including intraperitoneal approaches with monoclonal antibodies, cellular therapies and vaccines, hormone therapy with well-known drugs such as tamoxifen, and gene therapy give promise for the future.
BoringC.C., SquiresT.S., TongT.Cancer statistics, 1995. CA Cancer J Clin.1995; 45: 12–13.
3.
HolmesF.A., KudelkaA.P., KavanaghJ.J.Current status of clinical trials with paclitaxel and docetaxel. In: GeorgG.I., ChenT.T., OjimaJ., eds. Taxane Anticancer Agents: Basic Science and Current Status. American Chemical Society Symposium Series 583. 1995: 33–57.
4.
KaufmanD.W., KellyJ.P., WelchW.R.Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol.1989; 130: 1142–1151.
OzolsR.F., YoungR.C.Chemotherapy of ovarian cancer. Semin Oncol.1991; 18: 222–232.
7.
WiltshawE., SubramarianS., AlexopoulosC.Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinium (II) at the Royal Marsden Hospital. Cancer Treat Rep.1979; 63: 1545–1548.
8.
McGuireW.P., RowinskyE.K.Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy. Semin Oncol.1991; 18: 255–269.
9.
PazdurR., KudelkaA.P., KavanaghJ.J.The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev.1993; 19: 351–386.
10.
ParnessJ., HorwitzS.B.Taxol binds to polymerized tubulin in vitro. J Cell Biol.1981; 91: 479–487.
11.
KavanaghJ., KudelkaA., FreedmanR.Taxotere (docetaxel): activity in platin refractory ovarian cancer and amelioration of toxicity. Proc Annu Meet Am Soc Clin Oncol.1994; 13: A732.
12.
PiccartM.J., GoreM., Ten Bokkel HuininkW.Taxotere (RP56976, NSC628503): an active new drug for the treatment of advanced ovarian cancer (OVCA). Proc Annu Meet Am Soc Clin Oncol.1993; 12: A280.
13.
AaproM., Pujade-LauraineE., LhommeC.EORTC Clinical Screening Group: phase II study of Taxotere in ovarian cancer. Ann Oncol.1994; 5: 202.
14.
FrancisP., SchneiderJ., HannL.Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol.1994; 12: 2301–2308.
15.
McGuireW.P., HoskinsW.J., BradyM.F.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med.1996; 334: 1–6.
BurrisH.A., RothenbergM.L., KuhnJ.G.Clinical trials with the topoisomerase I inhibitors. Semin Oncol.1992; 19: 663–669.
18.
SlichenmyerW.J., RowinskyE.K., DonehowerR.C.The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst.1993; 85: 271–291.
19.
KudelkaA., EdwardsC., FreedmanR.An open phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc Annu Meet Am Soc Clin Oncol.1993; 12: A821.
20.
MoriH., ItohN., KondohH.Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative. Eur J Cancer.1992; 28: 613.
21.
TakeuchiS., TakamizawaH., TakedaY.Clinical study of CPT-11, camptothecin derivative, on gynecological malignancy. Proc Annu Meet Am Soc Clin Oncol.1991; 10: A617.
22.
NodaK.Late phase II study of CPT-11, new camptothecin derivative, in cervical and ovarian carcinoma. Proceedings of the 13th World Congress of Gynecology and Obstetrics (FIGO). 1991: 271. Abstract 0936.
23.
TakeuchiS., DobashiI., FujimotoS.A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn J Cancer Chemother.1991; 18: 1681–1689.
24.
GandiaD., AbigergesD., ArmandJ.P.CPT-11-induced cholingeric effects in cancer patients. J Clin Oncol.1993; 11: 196–197.
25.
VerschraegenC.F., NatelsonE., GiovanellaB.Phase I study of oral 9-nitro-camptothecin. Proc Annu Meet Am Soc Clin Oncol.1996. In press.
26.
LundC.Y., KristjansenP.E., HansenH.H.Clinical and preclinical activity of 2',2'-difluorodeoxytidine (gemcitabine). Cancer Treat Rev.1993; 19: 45–55.
27.
LundB., HansenO.P., TheiladeK.Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst.1994; 86: 1530–1533.
28.
OlivierS., FormentoP., FischelJ.L.Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. Eur J Cancer.1990; 26: 867–871.
29.
BernsE.M., SchuurmansA.L., BoltJ.Antiproliferative effects of suramin on androgen responsive tumor cells. Eur J Cancer.1990; 26: 470–474.
30.
HosangM.Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem.1985; 29: 265–273.
31.
PollakM., RichardM.Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst.1990; 82: 1349–1352.
32.
KikuchiY., HirataJ., HisanoA.Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II). Gynecol Oncol.1995; 58: 11–15.
StewartJ.S., HirdV., SnookD.Intraperitoneal, 131I and 90 Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer.1988; 3(Suppl): 71–76.
35.
RosenblumM.G., MurrayJ.L., KudelkaA.P.Pharmacokinetic studies with 90YB72.3 intraperitoneal administration in patients with ovarian cancer. Cancer Immunol Immunother.1996. In press.
RosenblumM.G., KavanaghJ.J., BurkeT.W.Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst.1991; 83: 1629–1636.
38.
KavanaghJ.J., KudelkaA., FreedmanR.The amelioration of toxicity of intraperitoneal monoclonal antibody 90 Y-B72.3 with EDTA: a phase I study in refractory ovarian cancer. Proc Annu Meet Am Assoc Cancer Res.1993; 34: A1332.
39.
BuckmanR., De AngelisC., ShawP.Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol.1992; 47: 102–109.
40.
SteisR.G., UrbaW.J., VanderMolenL.A.Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol.1990; 8: 1618–1629.
41.
StewartJ.A., BelinsonJ.L., MooreA.L.Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res.1990; 50: 6302–6310.
42.
FreedmanR.S., EdwardsC., KavanaghJ.Intraperitoneal (ip) adoptive immunotherapy of epithelial ovarian carcinoma (EOC) with recombinant interleukin-2 (rIL-2)-expanded tumor-infiltrating lymphocytes (TIL) plus low-dose rIL-2. Proc Annu Meet Am Soc Clin Oncol.1993; 12: A840.
43.
BolhuisR.L., LamersC.H., GoeyS.H.Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer.1992; 7: 78–81.
44.
PriceM.R., ClarkeA.J., RobertsonJ.F.Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11. Cancer Immunol Immunother.1990; 31: 269–272.
MacLeanG.D., ReddishM., KogantyR.R.Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother.1993; 36: 215–222.
47.
BerdD., MastrangeloM.J., EngsronP.F.Augmentation of the human immune response by cyclophosphamide. Cancer Res.1982; 42: 4862–4866.
48.
FungP.Y., LongeneckerB.M.Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res.1991; 51: 1170–1176.
49.
NorthR.J.Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor-induced suppressor T cell. J Exp Med.1982; 155: 1063–1074.
50.
TurkJ.L., ParkerD.Effect of cyclophosphamide on immunological control mechanisms. Immunol Rev.1982; 65: 99–113.
HoskinsP.J., O'ReillyS.E., SwenertonK.D.The “failure free interval” defines the likelihood of resistance to carboplatinum in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer.1991; 1: 205–208.
PagelJ., RoseC., ThorpeS.M.Treatment of advanced ovarian carcinoma with tamoxifen: a phase II trial. Proceedings of the 2nd European Conference of Clinical Oncology. 1983: 5–29.
OsborneR.J., MalikS.T., SlevinM.L.Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule. Br J Cancer.1988; 57: 115–116.
63.
HatchK.D., BeechamJ.B., BlessingJ.A.Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: a Gynecologic Oncology Group Study of second-line therapy in 105 patients. Cancer.1991; 68: 269–271.
64.
AhlgrenJ.D., EllisonN.M., GottliebR.J.Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol.1993; 11: 1957–1968.
65.
Van Der VeldenJ., GitschG., WainV.Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer.1995; 5: 301–305.
66.
ScambiaG., RanellettiF.O., Benedetti PaciniP.Type II estrogen binding sites in a lymphoblastoid line and growth-inhibitory effect of estrogen, antiestrogen and bioflavonoids. Int J Cancer.1990; 46: 1112–1116.
67.
ScambiaG., RanellettiF.O., Benedetti PaciniP.Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MFC-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemother Pharmacol.1991; 28: 255–258.
68.
GeisingerK.R., BerensM.E., DuckettY.The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro. Cancer.1990; 65: 1055–1061.
69.
ScambiaG., RanellettiF.O., Benedetti PaciniP.Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. Eur J Cancer.1992; 28: 1885–1889.
70.
SchwartzP.E., ChambersJ.T., KohornE.I.Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer: a prospective randomized trial. Cancer.1989; 63: 1074–1078.
71.
EmonsG., PahwaG.S., BrackC.Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol.1989; 25: 215–221.
72.
PahwaG.S., VollmerG., KnuppenR.Photoaffinity labelling of gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Biochem Biophys Res Commun.1989; 161: 1086–1092.
73.
EmonsG., OrtmannO., BeckerM.High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res.1993; 53: 5439–5446.
74.
AdelsonM.D., ReeceM.T.Effects of gonadotropin-releasing hormone analogues on ovarian epithelial tumors. Clin Obstet Gynecol.1993; 36: 690–700.
75.
PetersonC.M., JollesC.J., CarrellD.T.GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol.1994; 52: 26–30.
76.
YanoT., PinskiJ., HalmosG.Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A.1994; 91: 7090–7094.
77.
YanoT., PinskiJ., RadulovicS.Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A.1994; 91: 1701–1705.
78.
FreemanS.M., AbboudC.N., WhartenbyK.A.The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res.1993; 53: 5274–5283.
79.
FreemanS.M., McCuneC., AngelC.Treatment of ovarian cancer using HSV-TK gene modified vaccine-regulatory issues. Hum Gene Ther.1992; 3: 342–349.
80.
HananiaE.G., DeisserothA.B.Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther.1994; 1: 21–25.
81.
HananiaE.G., FuS., ZuZ.Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Therapy.1995; 2: 285–294.
